RxDoctor Payments Data

Marsha Smith, MD

Neurology · Cincinnati, OHNPI 1528003548

Payments from drug & device makers

$183,046in general payments, 2019–2025

Across 658 payments — averaging $278.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$109K
  • Kyowa Kirin, Inc.$43K
  • MDD US Operations, LLC$13K
  • Ipsen Pharma SAS$5K
  • Abbott$5K
  • Boston Scientific$2K
  • plus $6K from 36 others

What the payments were for

  • Consulting fees$6,5804%
  • Speaking & faculty fees$147,59183%
  • Travel & lodging$9,0345%
  • Food & beverage$14,6318%
  • Education$1060%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$183,046 in reported general payments places this provider in the 85th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$204,521
Medicare patients
438
Services billed
5,832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate22$190,528
NuplazidPimavanserin Tartrate29$141,012
GocovriAmantadine Hcl24$73,744
QuliptaAtogepant25$40,272
Galantamine ErGalantamine Hbr240$27,269
Rasagiline Mesylate83$17,215
Carbidopa-LevodopaCarbidopa/Levodopa591$15,812
XcopriCenobamate12$12,104
Memantine Hcl ErMemantine Hcl92$12,040
Memantine Hcl257$9,925
Pramipexole ErPramipexole Di-Hcl17$8,709
Primidone242$7,334
Rivastigmine11$5,059
Carbidopa-Levodopa ErCarbidopa/Levodopa107$3,563
Levetiracetam90$3,521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$210$190,52822 claims
Acadia Pharmaceuticals IncNuplazid$189$141,01229 claims
MDD US Operations, LLCGocovri$13,250$73,74424 claims
AbbVieQulipta$109,483$40,27225 claims
SK Life Science, Inc.Xcopri$528$12,10412 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$130$2,60529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 702 neurology providers in Ohio.

Other neurology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →